Maternal Opioid Use and Neonatal Abstinence Syndrome: Scoring and Treatment Guide

Introduction: The Growing Challenge of Neonatal Abstinence Syndrome

Neonatal abstinence syndrome (NAS) represents one of the most significant neonatal care challenges worldwide, driven by the global opioid epidemic. In developed countries, NAS incidence has increased 5-7 fold over the past decade. While India's opioid crisis profile differs from Western countries, opium and pharmaceutical opioid misuse is significant in states like Punjab, Rajasthan, Manipur, and Mizoram. The United Nations Office on Drugs and Crime (UNODC) reports India has approximately 2.1 million opioid users, with a significant proportion being women of reproductive age.

This comprehensive guide covers the pathophysiology of NAS, the Finnegan Neonatal Abstinence Scoring System, evidence-based pharmacological and non-pharmacological treatment protocols, and the Indian clinical context. Understanding NAS recognition and management is essential for neonatal teams across Indian hospitals, as even occasional cases require systematic, protocol-driven care to optimize outcomes.

Pathophysiology of Neonatal Opioid Withdrawal

Fetal Opioid Exposure and Dependence

All opioids cross the placenta through simple diffusion, with fetal exposure proportional to maternal dose, drug lipophilicity, and duration of use. Chronic opioid exposure during pregnancy leads to fetal physiological dependence through several mechanisms.

• Mu-opioid receptor upregulation: Chronic fetal opioid exposure leads to increased receptor density and sensitivity, a compensatory response to sustained receptor activation.
• Noradrenergic system adaptation: The locus coeruleus, the brain's primary norepinephrine center, is chronically suppressed by opioids. At birth, when opioid supply ceases, unopposed noradrenergic hyperactivity produces the characteristic sympathetic symptoms of withdrawal.
• Cyclic AMP pathway upregulation: Intracellular signaling pathways compensate for chronic opioid-mediated inhibition, becoming hyperactive upon drug removal.
• Gastrointestinal opioid receptor dependence: Enteric nervous system opioid receptors adapt to chronic stimulation, and withdrawal causes increased gut motility, secretion, and cramping.

Factors Influencing NAS Severity

The severity and timing of NAS depend on multiple maternal, drug, and neonatal factors that should be assessed prenatally to anticipate neonatal needs.

Factor	Effect on NAS	Clinical Implication
Opioid type	Short-acting: earlier onset; long-acting: delayed onset	Heroin NAS appears in 24-48 hours; methadone NAS in 48-72 hours or later
Maternal dose	Higher doses increase NAS severity	Dose reduction before delivery is not recommended due to relapse and fetal stress risks
Polydrug use	Benzodiazepines, SSRI, and tobacco worsen NAS	Comprehensive maternal drug history is essential
Gestational age	Preterm infants may have milder NAS	Immature CNS and lower receptor density may attenuate withdrawal
Breastfeeding	Reduces NAS severity	Strongly encouraged for stable maintenance patients
Rooming-in	Reduces NAS scores and treatment need	Mother-infant dyad care is preferred over NICU admission when possible

Clinical Presentation of NAS

Symptom Domains

NAS manifests across four symptom domains, with onset timing dependent on the half-life of the opioid involved. Short-acting opioids like heroin produce symptoms within 24-48 hours, while methadone-related NAS may not appear for 48-96 hours and occasionally up to 7 days.

1. Central nervous system hyperirritability: High-pitched cry, tremors (initially with stimulation, then spontaneous), increased muscle tone, hyperactive Moro reflex, sleep disturbance (sleeping less than 1-2 hours after feeding), excoriation from excessive movement, and seizures (in 2-11% of cases)
2. Gastrointestinal dysfunction: Poor feeding, uncoordinated suck-swallow, vomiting, diarrhea, excessive weight loss (more than 10% birth weight), and dehydration
3. Autonomic dysregulation: Sweating, fever, mottling, nasal stuffiness, frequent sneezing and yawning, temperature instability
4. Respiratory symptoms: Tachypnea (respiratory rate above 60/min), nasal flaring, retractions, though severe respiratory distress is uncommon in isolated opioid NAS

Finnegan Neonatal Abstinence Scoring System

Scoring Components and Protocol

The Finnegan Neonatal Abstinence Scoring System, developed by Loretta Finnegan in 1975 and subsequently modified, remains the gold standard for NAS assessment worldwide, including in Indian NICUs. It assigns weighted scores across 21 clinical parameters assessed systematically every 4 hours.

Category	Scored Items	Maximum Points
CNS disturbances	Cry, sleep, Moro reflex, tremors, tone, excoriation, myoclonic jerks, seizures	Up to 20
Metabolic/vasomotor	Sweating, fever (37.2-38.2C or above 38.2C), mottling	Up to 6
Respiratory	Nasal stuffiness, sneezing, flaring, respiratory rate	Up to 6
GI disturbances	Excessive sucking, poor feeding, regurgitation, loose/watery stools	Up to 9

Treatment decision thresholds based on Finnegan scores are as follows: scores consistently below 8 indicate supportive care only; three consecutive scores of 8 or above indicate need for pharmacological treatment initiation; scores above 12 despite initial treatment indicate dose escalation; and declining scores below 8 for 48-72 hours allow weaning initiation.

Management of NAS

Non-Pharmacological Care: The Foundation

Non-pharmacological interventions should be implemented for all opioid-exposed neonates regardless of withdrawal severity. These measures reduce NAS scores, decrease the need for pharmacological treatment, and shorten hospital stays.

• Rooming-in with mother: Keeping the mother-infant dyad together reduces NAS scores by 30-40% compared to NICU admission. NNF India supports rooming-in for stable infants with mothers who are on supervised maintenance therapy.
• Breastfeeding: Unless contraindicated (active illicit drug use, HIV in some settings), breastfeeding is strongly encouraged. Small amounts of methadone or buprenorphine in breast milk provide gradual weaning effect.
• Swaddling: Gentle containment in a snug wrap reduces startle responses and promotes sleep between feeds.
• Low-stimulation environment: Dim lighting, minimal noise, clustered care activities, and limited handling reduce sensory overload.
• Skin-to-skin contact: Kangaroo Mother Care stabilizes vital signs and promotes bonding. NNF India guidelines strongly advocate KMC for NAS infants.
• Small frequent feeds: Higher caloric density formula (22-24 kcal/oz) may be needed for infants with excessive caloric expenditure from hyperirritability and diarrhea.

Pharmacological Treatment Protocols

When Finnegan scores remain consistently at 8 or above despite optimal non-pharmacological care, pharmacological intervention is initiated. Oral morphine sulfate is the first-line agent in most protocols worldwide and in India.

1. Morphine initiation: 0.05-0.1 mg/kg/dose every 3-4 hours orally. Dose is titrated upward by 0.05 mg/kg/dose every 24 hours if scores remain elevated.
2. Dose stabilization: Once scores are consistently below 8 for 48 hours, the stabilization dose is maintained for 48-72 hours before weaning begins.
3. Weaning protocol: Reduce dose by 10-20% every 24-48 hours, guided by Finnegan scores. If scores rise above 8 during weaning, return to the last effective dose.
4. Discontinuation: Morphine is stopped when the dose reaches 0.02 mg/kg/dose. Monitor for 48-72 hours off medication before discharge.

Adjunctive Pharmacotherapy

Phenobarbital is the most common second-line agent for NAS refractory to morphine alone, particularly when polydrug exposure is suspected. Loading dose of 15-20 mg/kg IV or oral, followed by maintenance of 3-5 mg/kg/day. Clonidine (0.5-1 mcg/kg every 4-6 hours) is an emerging adjunctive therapy that targets the noradrenergic hyperactivity underlying withdrawal symptoms.

Newer Approaches: Eat-Sleep-Console Method

The Eat-Sleep-Console (ESC) method represents a paradigm shift from Finnegan-based scoring to a function-based assessment of NAS management. Instead of detailed numerical scoring, ESC asks three simple questions: can the infant eat adequately? Can the infant sleep for at least an hour? Can the infant be consoled within 10 minutes? If yes to all three, supportive care continues. If not, treatment escalation is considered. Early adopter studies show ESC reduces pharmacological treatment rates by 25-40%, shortens hospital stays by 5-8 days, and maintains safety. NNF India is evaluating ESC implementation feasibility in Indian NICUs.

Indian Context: Opioid Use Patterns and NAS

Regional Opioid Use Patterns

India's opioid use landscape differs from Western countries but poses significant NAS risk in specific populations. Punjab has the highest prevalence of opioid use disorder, with an estimated 2-3% of the population affected. Other states with significant opioid use include Rajasthan (opium use in certain communities), Manipur and Mizoram (injectable heroin), and metropolitan cities (pharmaceutical opioid misuse including tramadol and codeine).

Traditional Opium Use in Pregnancy

In parts of Rajasthan, Madhya Pradesh, and Uttar Pradesh, opium (afeem) use is culturally embedded, with some women continuing use during pregnancy. These infants may present with NAS that is not initially recognized if maternal opium use is not disclosed. Cultural sensitivity in history-taking and awareness of regional substance use patterns are essential for Indian neonatologists and pediatricians.

NAS Management in Indian NICUs

NAS management capacity varies across Indian healthcare facilities. Tertiary NICUs in metropolitan centers generally have Finnegan scoring protocols and morphine treatment availability. However, district and rural hospitals may lack systematic scoring tools, trained nursing staff for regular assessments, and oral morphine formulations. NNF India recommends building NAS management capacity at all district hospitals in high-prevalence states, with structured referral pathways for complex cases requiring prolonged pharmacotherapy.

Discharge Planning and Follow-Up

NAS infants require comprehensive discharge planning that addresses both medical and psychosocial needs. The average NAS hospitalization is 14-21 days, but some infants on prolonged weaning may require 30-60 days of treatment.

1. Medical discharge criteria: Off all pharmacotherapy for 48-72 hours with stable Finnegan scores, adequate weight gain (20-30 g/day), and established feeding pattern.
2. Safe home environment: Social work assessment confirming safe discharge environment, adequate caregiver capacity, and absence of active substance abuse in the household.
3. Follow-up schedule: Pediatric follow-up at 1 week, 2 weeks, 1 month, then monthly for 6 months. Developmental assessment at 6, 12, 18, and 24 months. HEAMAC neonatal care resources support structured home monitoring and developmental follow-up tracking.
4. Maternal support: Ensure ongoing addiction treatment linkage, postpartum mental health screening, and social support services.
5. Immunization: NAS does not affect standard immunization schedules. Hepatitis B vaccination at birth is particularly important given the association between injection drug use and hepatitis B/C.

Conclusion: Systematic NAS Management for Optimal Neonatal Outcomes

Neonatal abstinence syndrome requires a structured, evidence-based approach combining comprehensive maternal history, systematic Finnegan scoring, prioritization of non-pharmacological care, protocol-driven pharmacotherapy when needed, and holistic discharge planning. In India, building NAS awareness and management capacity beyond tertiary centers is essential, particularly in high-prevalence regions. With appropriate care, NAS is a treatable condition with favorable long-term outcomes when coupled with supportive environments and developmental follow-up.